| Bioactivity | Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets Thrombin. Ichorcumab binds to exosite 1 on thrombin and inhibits substrate binding but not catalytic activity. The isotype control for Ichorcumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)[1]. |
| Invitro | Ichorcumab (JNJ-9375) 通过与凝血酶上的外部位点 1 结合并防止其与凝血酶相互作用来延长凝血时间纤维蛋白原和其他底物，如因子 V 和 VIII 以及蛋白酶激活受体 1。由于 Ichorcumab 不影响凝血酶的催化活性，因此与阻断凝血酶或因子 Xa 活性位点的抗凝剂相比，Ichorcumab 可能产生更少的出血[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Ichorcumab 相关抗体: |
| CAS | 2589583-20-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Weitz JI, et al. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. J Thromb Haemost. 2019 Dec;17(12):2081-2088. |